Moreover, the pre-treatment with ADP promoted Bcl-2 down-regulation induced by cisplatin, a strong and widely used cancer chemotherapy drug, in both HUVEC (Figure 7F) and THP1 (Figure 7G). Here, BCL2 is linked to cancer.